RBL2 and breast cancer: Third, we did not perform mechanistic studies by injection of invasive-competent or metastasis-competent BC cells, e.g., MCF-7 or MDA-MB-231 cells, in NSG mice to monitor mTORC1/mTORC2 activities, and their effect on biomarkers of proliferation (Ki67/PCNA) and quiescence (RBL2/CDKN1A) in different phases of the metastatic cascade, and/or any association between mTORC1/mTORC2 signaling and genomic instability.